New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 10, 2014
16:09 EDTVSTMVerastem says lead cancer stem cell inhibitor VS-6063 continues to show promise
Verastem hosted its annual Research and Development Day, at which it reports it said, "We continue to see promising clinical signals from the VS-6063 program. An additional partial response has been reported since our interim report at ASCO on the combination of VS-6063 and weekly paclitaxel in twenty-two patients with ovarian cancer. To date, best clinical response of at least stable disease has been observed in 14 of the 22 patients. This comprises two complete responses, three partial responses and nine patients with stable disease, including four patients whose disease has been stable for 6 months or longer. Eight patients continue on study drug. Based on this encouraging activity, we are planning a controlled Phase 2 study in patients with platinum resistant ovarian cancer. The company also noted that it has made "significant progress in the past 12 months and have continued to further scientific understanding with all of our product candidates." Encouraged by these initial signs of clinical activity, the company reported it is adding additional studies to further test its hypothesis that the targeting of cancer stem cells may enable a more durable clinical response.
News For VSTM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 30, 2014
07:09 EDTVSTMVerastem reports Q3 EPS (52c), consensus (52c)
Subscribe for More Information
October 24, 2014
06:09 EDTVSTMVerastem presents new data on Mesothelioma programs
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use